Dengue hemorrhagic fever in a Japanese traveler who had preexisting Japanese encephalitis virus antibody
10.2149/tmh.2014-34
- Author:
Rumi Sato
;
Nobuyuki Hamada
;
Takahito Kashiwagi
;
Yoshihiro Imamura
;
Koyu Hara
;
Yoshiko Naito
;
Natsuko Koga
;
Munetsugu Nishimura
;
Tomoko Kamimura
;
Tomohiko Takasaki
;
Hiroshi Watanabe
;
Takeharu Koga
- Publication Type:Journal Article
- Keywords:
dengue hemorrhagic fever;
Japanese encephalitis virus antibody;
cross-reactive antibody;
imported infection;
petechiae;
thrombocytopenia;
antibody-dependent enhancement (ADE)
- From:Tropical Medicine and Health
2015;advpub(0):-
- CountryJapan
- Language:English
-
Abstract:
A patient, an adultJapanese traveler who had just returned from Thailand, had developed denguehemorrhagic fever (DHF). A primary infection of dengue virus (DENV) wasconfirmed, in particular, DENV serotype 2 (DENV-2) via the detection of the virusgenome, a significant increase in its specific neutralizing antibody and the isolationof DENV-2. DHF is often observed following a secondary infection from another serotypeof dengue virus, particularly in children, but this case was a primaryinfection of DENV. Japan is a non-endemic country of dengue disease. Instead,only Japanese encephalitis (JE) is known to be an endemic flavivirus family. Inthis study, IgG antibody against Japanese encephalitis virus (JEV) was detected.JEV belongs to the family of dengue virus and prevails in Japan, particularly inKyushu. Among many risk factors for the occurrence of DHF, a plausiblecandidate could be a cross-reactive antibody-dependent enhancement (ADE)mechanism by JEV antibody. This indicates that most Japanese travelers, wholive in non-endemic areas of dengue, particularly in Kyushu, should payattention to the occurrence of DHF.
